

Pharma Market Update

Key Trends and forecasts

Výročná konferencia FARMAKON SR 2025
29.4.2024 – HOTEL TATRA Bratislava

Jozef Urbín | Healthcare Solutions Manager, IQVIA

Disclaimer

The analyses, their interpretation, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the completeness or accuracy of such third party sources or data.

As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to certain risks and uncertainties, and are not to be considered guarantees of any particular outcome.

All reproduction rights, quotations, broadcasting, publications reserved. The contents of this presentation are confidential, and no part of this presentation may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without express written consent of IQVIA.

Copyright © 2025 IQVIA. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States and various other countries.

List of Abbreviations

- AI: Artificial Intelligence
- APAC: Asia-Pacific
- CAGR: Compound Annual Growth Rate
- CEE: Central and Eastern Europe
- CH: Consumer Health
- CIS: Commonwealth of Independent States
- EEA: European Economic Area
- EFPIA: European Federation of Pharmaceutical Industries and Associations
- EMEA: Europe, Middle East, and Africa
- ESG: Environmental, Social, and Governance
- EU4 : Germany, Spain, Italy, France
- HTA: Health Technology Assessment
- JCA: Joint Clinical Assessment
- LATAM: Latin America
- LCEUR: Local Currency Euro
- LY: Last Year
- MAT: Moving Annual Total
- PAC: Patient Care
- PCY: Pharmacy
- PEC: Personal Care
- PI: Parallel Import
- RWE: Real-World Evidence
- Rx: Prescription Drugs
- SE: Southeast Asia
- Tx: Treatments
- Vx: Vaccines
- WE: Western Europe
- YoY: Year-over-Year

Agenda

01| Global Trends

02| Comparison of CEE Countries

03| Slovak Pharma Sector Overview

04| Q&A




01

Global Trends

Nine issues/trends impacting healthcare and prescription medicine markets that are new or inflecting from 2025 onwards

Global view




East Europe comprise 4% of global market with CEE having the highest growth expectations in the long term

Pharma market overview [Rx + regOTC]


Global view

Size of pharma markets and their share in global market, 2024 [% in LCEUR]



CEE: Poland, Romania, Hungary, Czech Republic, Slovakia, Croatia, Bulgaria, Slovenia, Lithuania, Serbia, Latvia, Bosnia, Estonia, Albania, Kosovo, Montenegro, Macedonia
 CIS: Russia, Kazakhstan, Uzbekistan, Mongolia, Moldova, Armenia, Azerbaijan, Belarus, Georgia, Kyrgyzstan, Tajikistan
 WE: Germany, France, UK, Italy, Spain, Netherlands, Belgium, Greece, Portugal, Sweden, Austria, Switzerland, Finland, Norway, Ireland
 EU4: Spain, Italy, Germany, France

Global pharma markets value and YoY growth of key regions, 2025-2028 [bn LCEUR]



Source: IQVIA Local Databases, MIDAS, Pharma market includes Retail and Hospital sales; IQVIA Market Prognosis Global 2024-2028 (Sep., 2024)

IQVIA | Výročná konferencia FARMAKON SR 2025 | CONFIDENTIAL – This document must not be shared with any 3rd party without previous IQVIA's written consent


Uneven recovery and stressed healthcare systems mark the post-pandemic pharma environment

Current global pharma market trends

Global view

Volume improves


Global Rx Volume
(Quarterly, Bn SU)



- Volume recovers, driven by Gx

Driven by generics


Global Rx Volume
(Annual, Bn SU)



- Innovative volume has been increasing since 2020 but remains below pre-COVID levels

Launches struggle

Median cumulative sales of innovative launches
(Mn USD, Top 8 Countries)*



- New launches introduce innovation
- Constrained healthcare system

Note: *Pre-COVID launches: 2017-2019, Post-COVID launches from 2020-H1 2023, Excludes Hep C products, COVID-19 Vaccines and Treatments, Countries in scope are US, EU4+UK, Japan & China

Source: IQVIA EMEA Thought Leadership; IQVIA MIDAS QTR Q4 2023; Rx-only, Innovation Insights; excludes vaccines


IQVIA | Výročná konferencia FARMAKON SR 2025 | CONFIDENTIAL – This document must not be shared with any 3rd party without previous IQVIA's written consent

Global Rx market grows 9% YoY to reach \$1.5 Tn, fuelled by specialty biologics

Global growth drivers

Global view

Global Rx List price sales [2014 – 2024, bn USD, CAGR]




Notes: Growth rates at constant exchange rates; data for all years is MAT Q3, COVID-19 vaccines & treatments excluded

Source: IQVIA EMEA Thought Leadership; IQVIA MIDAS MAT Q3 2024; Rx-only


IQVIA | Výročná konferencia FARMAKON SR 2025 | CONFIDENTIAL – This document must not be shared with any 3rd party without previous IQVIA's written consent

Drivers of Global Growth 2023-24 [bn USD]



Global value is highly concentrated in a few top therapy areas – exclusive of COVID-19 Vx & Tx

Sales in therapy areas in 2024



Note: Growth rates at constant exchange rates

Source: IQVIA EMEA Thought Leadership; IQVIA MIDAS MAT Q3 2024; Rx-only

Abbvie reported highest sales in 2024, closely followed by J&J; highest YoY growth of 24% was reported for Lilly

Top 10 Corporations by latest sales

Global view

Top 10 corporations by sales [2024, bn USD]

Rank	Corporation	2024 sales	YoY growth
1	Abbvie	87.9	3%
2	Johnson & Johnson	81.2	6%
3	Novo Nordisk	77.0	12%
4	Eli Lilly	72.8	24%
5	Bristol Myers Squibb	66.7	15%
6	Merck	55.8	8%
7	AstraZeneca	54.1	10%
8	Sanofi	53.5	4%
9	Pfizer	53.5	18%
10	Roche	53.4	7%

Growth rates at constant exchange rates

Source: IQVIA EMEA Thought Leadership; IQVIA MIDAS 2024; Rx-only


IQVIA | Výročná konferencia FARMAKON SR 2025 | CONFIDENTIAL – This document must not be shared with any 3rd party without previous IQVIA’s written consent

Ozempic is the #1 global brand reaching 45.5 bn USD in 2024, Mounjaro recorded the highest YoY growth (92%)

Top 10 Global brands by latest sales

Global view

Top 10 global brands by sales value [2024, bn USD]



Growth rates at constant exchange rates

Source: IQVIA EMEA Thought Leadership; IQVIA MIDAS 2024; Rx-only

IQVIA | Výročná konferencia FARMAKON SR 2025 | CONFIDENTIAL – This document must not be shared with any 3rd party without previous IQVIA’s written consent

European Parallel Import (PI) sales reached €7.39bn with substantial growth of +15% in MAT 12'24

PI overview across EEA+UK

Import markets context

Size

€7.39bn

Growth

+15% PI (+987 EUR mil)
+9% Non-PI growth
+9% Total market growth


Share

2.4% PI
Across EEA

Impact


~4,000 brands
Across ~20 import countries

European annual parallel imports [EUR Bn sales, EEA+UK]



Total Availability by approval year (2019-2024)

The **total availability by approval year** is the number of medicines available to patients in European countries as of 5th January 2024 (for most countries this is the point at which the product gains access to the reimbursement list), split by the year the product received marketing authorization in Europe.



New WAIT report will be published 8.5.2025

European Union average: 72 products available (43%). In most countries availability equates to granting of access to the reimbursement list, except in DK, FI, LU, NO, SE where some hospital products are not covered by the general reimbursement scheme.

Sources: IQVIA


IQVIA | Výročná konferencia FARMAKON SR 2025 | CONFIDENTIAL – This document must not be shared with any 3rd party without previous IQVIA's written consent

02

Comparison of CEE Countries

Poland is by far the largest market, Romania ahead of Czechia, Slovakia in top 5 highest Rx per capita sales

CEE region overview



Central & Eastern Europe

Country	Rx Pharma market absolute value 2024 [m LCEUR]	CAGR [% , 2022-2024]	Rx per capita [LCEUR, 2024]
POLAND	10,570	18.1%	234
ROMANIA	5,187	15.6%	235
CZECH	4,135	8.3%	371
HUNGARY	2,703	10.4%	268
BULGARIA	2,326	15.2%	312
SLOVAKIA	1,839	11.1%	300
CROATIA	1,464	12.1%	338
SERBIA	1,261	13.3%	165
SLOVENIA	912	9.4%	394
LITHUANIA	861	14.5%	265
LATVIA	398	14.5%	186
BOSNIA	387	9.7%	109
ESTONIA*	302	13.9%	197

Note: Estonia without hospital sales



Source: IQVIA, World Bank

East Europe outperformed global market with last year growth of 14%, driven mainly by Oncology & Alimentary Tract & Metabolism

CEE segment size

Central & Eastern Europe

Market value split by ATC 1, CEE [LCEUR bn, Rx market, 2022 - 2024]



Note: CEE = Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Serbia, Slovakia, Slovenia; EU5 = France, Germany, Italy, Spain, UK

Source: IQVIA MIDAS

IQVIA | Výročná konferencia FARMAKON SR 2025 | CONFIDENTIAL – This document must not be shared with any 3rd party without previous IQVIA's written consent

Novartis and AstraZeneca lead the market with each having 5.1% market share

Top 10 CEE Companies [Rx + regOTC]

Central & Eastern Europe

#	Corporation	MS 2024 [%]	2022 [LCEUR m]	2023 [LCEUR m]	2024 [LCEUR m]	YoY 2023-2024 [%]	CAGR 2022-2024 [%]	Key products
1	NOVARTIS	<div><div></div></div> 5.1%	<div><div></div></div> 1,297	<div><div></div></div> 1,505	<div><div></div></div> 1,649	<div><div></div></div> 10%	<div><div></div></div> 13%	Entresto, Zolgensma, Jakavi, Kisqali, Cosentyx, Kesimpta
2	ASTRAZENECA	<div><div></div></div> 5.1%	<div><div></div></div> 847	<div><div></div></div> 1,169	<div><div></div></div> 1,647	<div><div></div></div> 41%	<div><div></div></div> 39%	Forxiga, Lynparza, Tagrisso, Imfinzi
3	MSD	<div><div></div></div> 5.0%	<div><div></div></div> 1,076	<div><div></div></div> 1,271	<div><div></div></div> 1,628	<div><div></div></div> 28%	<div><div></div></div> 23%	Keytruda, Gardasil 9
4	ROCHE	<div><div></div></div> 4.8%	<div><div></div></div> 1,147	<div><div></div></div> 1,376	<div><div></div></div> 1,542	<div><div></div></div> 12%	<div><div></div></div> 16%	Tecentriq, Ocrevus, Parjeta, Kadcyla, Evrysdi
5	JOHNSON & JOHNSON	<div><div></div></div> 4.4%	<div><div></div></div> 958	<div><div></div></div> 1,141	<div><div></div></div> 1,417	<div><div></div></div> 24%	<div><div></div></div> 22%	Imbruvica, Darzalex, Stelara, Erleada, Tremfya
6	PFIZER	<div><div></div></div> 3.6%	<div><div></div></div> 913	<div><div></div></div> 1,068	<div><div></div></div> 1,165	<div><div></div></div> 9%	<div><div></div></div> 13%	Eliquis, Ibrance, Enbrel
7	NOVO NORDISK	<div><div></div></div> 3.5%	<div><div></div></div> 756	<div><div></div></div> 969	<div><div></div></div> 1,126	<div><div></div></div> 16%	<div><div></div></div> 22%	Ozempic, Rybelsus, Saxenda, Tresiba, NovoRapid, Xultophy
8	SANOFI	<div><div></div></div> 2.9%	<div><div></div></div> 819	<div><div></div></div> 879	<div><div></div></div> 928	<div><div></div></div> 6%	<div><div></div></div> 6%	Clexane, Toujeo, Dupixent, Praluent
9	SERVIER	<div><div></div></div> 2.8%	<div><div></div></div> 749	<div><div></div></div> 812	<div><div></div></div> 901	<div><div></div></div> 11%	<div><div></div></div> 10%	Triplixam, Detralex, Milurit, Prestarium, Lonsurf
10	SANDOZ	<div><div></div></div> 2.5%	<div><div></div></div> 702	<div><div></div></div> 748	<div><div></div></div> 816	<div><div></div></div> 9%	<div><div></div></div> 8%	Omnitrope, Hyrimoz, Binocrit, Amoksiklav
Top 10		40%	3,265	10,937	12,818	17%	18%	
Others		60%	15,613	17,483	19,527	18%	12%	
Total		100%	24,878	28,420	32,345	14%	14%	

Note: CEE = Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Serbia, Slovakia, Slovenia

Source: IQVIA MIDAS

Keytruda dominates the CEE market with EUR 1.3bn annual sales

Top 10 CEE brands

Central & Eastern Europe

#	Brand	ATC2	Corporation	MS 2024 [%]	2024 sales [LCEUR m]	YoY 2023 vs. 2024 [%]	CAGR 2022-2024 [%]
1	KEYTRUDA	L1 (ANTINEOPLASTICS)	MSD	<div><div></div></div> 4,0%	<div><div></div></div> 1,300	<div><div></div></div> 37%	<div><div></div></div> 37%
2	OPDIVO	L1 (ANTINEOPLASTICS)	BMS	<div><div></div></div> 1,8%	<div><div></div></div> 572	<div><div></div></div> 26%	<div><div></div></div> 26%
3	OZEMPIC	A10 (DRUGS USED IN DIABETES)	Novo Nordisk	<div><div></div></div> 1,6%	<div><div></div></div> 514	<div><div></div></div> 35%	<div><div></div></div> 58%
4	ELIQUIS	B1 (ANTITHROMBOTIC AGENTS)	Pfizer	<div><div></div></div> 1,5%	<div><div></div></div> 494	<div><div></div></div> 11%	<div><div></div></div> 17%
4	DARZALEX	L1 (ANTINEOPLASTICS)	Johnson & Johnson	<div><div></div></div> 1,3%	<div><div></div></div> 406	<div><div></div></div> 51%	<div><div></div></div> 68%
5	XARELTO	B1 (ANTITHROMBOTIC AGENTS)	Bayer	<div><div></div></div> 1,2%	<div><div></div></div> 392	<div><div></div></div> -29%	<div><div></div></div> -13%
6	JARDIANCE	A10 (DRUGS USED IN DIABETES)	Boehringer Ingelheim	<div><div></div></div> 0,9%	<div><div></div></div> 301	<div><div></div></div> 49%	<div><div></div></div> 61%
7	IMBRUVICA	L1 (ANTINEOPLASTICS)	Johnson & Johnson	<div><div></div></div> 0,9%	<div><div></div></div> 294	<div><div></div></div> 11%	<div><div></div></div> 13%
9	XTANDI	L2 (CYTOSTATIC HORMONE THER)	Astellas	<div><div></div></div> 0,9%	<div><div></div></div> 278	<div><div></div></div> 6%	<div><div></div></div> 13%
10	FORXIGA	A10 (DRUGS USED IN DIABETES)	AstraZeneca	<div><div></div></div> 0,8%	<div><div></div></div> 274	<div><div></div></div> 51%	<div><div></div></div> 68%
Others				86%	27,863	12%	12%
Total				100%	323,450	14%	14%

Note: CEE = Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Serbia, Slovakia, Slovenia


Source: IQVIA MIDAS

IQVIA | Výročná konferencia FARMAKON SR 2025 | CONFIDENTIAL – This document must not be shared with any 3rd party without previous IQVIA’s written consent

Pharma growth in Europe is slowing down amidst growing pressures in key markets

Major segments growth [Rx + regOTC]

Central & Eastern Europe



Notes: Bubble size indicates 2024 sales, Growth calculated using constant exchange rates; Rebates and discounts are not considered; Contains Audited + Unaudited data

Source: Global Market Prognosis Sep 2024


IQVIA | Výročná konferencia FARMAKON SR 2025 | CONFIDENTIAL – This document must not be shared with any 3rd party without previous IQVIA's written consent

The prognosis for CEE region predicts pharma market growth of 9.2% in the following 3 years

CEE Market Prognosis forecast [Rx + regOTC]

Central & Eastern Europe

CEE countries total pharma market prognosis [LCEUR bn, 2025 – 2028]



1) Baltics include Lithuania, Latvia and Estonia 2) Adriatics include Croatia, Serbia and Bosnia & Herzegovina

03

Slovak Pharma Sector Overview

On the left side of the slide, there are several overlapping rounded rectangular shapes in shades of blue and teal. A large dark blue shape is the most prominent, with a lighter blue shape above it and a teal shape below it. A thin blue line also curves around the bottom right of the large dark blue shape.

2 | Slovak Pharma Sector Overview

Rx

We have identified “9 hot topics” in the Slovak Republic that will shape pharma and healthcare sectors in 2025 going forward

Factors influencing Slovak healthcare system

Aging population, behavioral risk (diet smoking), low disease prevention (but e.g. new cardio vascular plan)

Program decree for 2025 published in March 2025

Hospital inefficiencies and system transparency

Increasing pressures on healthcare spending, low healthcare spending to GDP, low to none payers reserves

Low data availability and low use of RWE

New launches, access to innovation, expensive Car T and cell & gene therapies

Digitalization not fully implemented

Global geo-political instability from Russia/Ukraine war to USA import tariffs/customs


Local/EU Legislative changes e.g. HTA for vaccines, safety stock, PICO framework (JCA), waste water, ESG

In last 5 years, SK pharma sector has grown by 9%, driven primarily by the performance of antineoplastics and immunomodulators

5 years of Slovak Rx pharma sector 2020-2024



SK pharma industry development [EUR bn, ex-mnf, Rx]




Last year the value of the SK pharma sector increased both in EUR sales (12.5% PPG) and in units (2.0% PPG)


SK Rx segment only: split by Ox¹, Gx², Biosimilars³ and Others⁴



SK Rx sales value [EUR bn, 2022-2024]



SK Rx volume [units m, 2022-2024]




Note: ¹Ox – Original Rx products protected by patent or with expired patent, ²Gx – Generic Rx products, ³Biosimilars – Biologic Rx product almost identical copy of an original product, ⁴Others – Other Rx products such as COVID-19 medicines, special joint lubrications, etc.

Retail is the leading sales channel, capturing 77% of last year's sales value; virtual PCYs account for 58% of retail sales


SK Rx segment split by channel



SK Rx sales value Retail/Hospital/Physician
[EUR bn, 2022-2024]



SK Rx Retail sales value Independent/Chain/Virtual
[EUR bn, 2022-2024]



Note: Top chains – Dr. Max, Benu, Farmakol ; Top virtual chains – Vasa Lekaren, Plus Lekaren, Partner Top
PCY- Pharmacy

Source: IQVIA Sell-in ex-MNF

IQVIA | Výročná konferencia FARMAKON SR 2025 | CONFIDENTIAL – This document must not be shared with any 3rd party without previous IQVIA's written consent

In 2024, Keytruda surged to the top with 57% growth, surpassing Eliquis, which dropped a spot, while growing 12%

Top 10 ranking of Rx brands



#	Brand (launch year)	Indication	Corporation	Sales & market share [2024, EUR m]	Value growth / decline [2024 vs 2023]	Position change [2024 vs 2023; change in position]
1	KEYTRUDA (2016)	Multiple onco: e.g. NSCLC, melanoma	MSD	<div><div></div>35.2 (2%)</div>	<div><div></div>57%</div>	<div><div></div>+1</div>
2	ELIQUIS (2012)	Deep vein thromb., atrial fib., pulm. embolism	PFIZER	<div><div></div>26.4 (1%)</div>	<div><div></div>12%</div>	<div><div></div>-1</div>
3	JARDIANCE (2014)	Type 2 diabetes, heart failure, chronic kidney disease	BOEHRINGER INGEL	<div><div></div>25.6 (1%)</div>	<div><div></div>84%</div>	<div><div></div>+6</div>
4	HUMIRA (2002)	Arthritis, psoriasis, CD1, UC2 & others	ABBVIE	<div><div></div>23.1 (1%)</div>	<div><div></div>3%</div>	<div><div></div>-1</div>
5	OZEMPIC (2017)	Type 2 diabetes, cardiovascular risk reduction, weight management	NOVO NORDISK	<div><div></div>20.3 (1%)</div>	<div><div></div>60%</div>	<div><div></div>+6</div>
6	IMBRUVICA (2015)	Leukemia CLL/ SLL2	JOHNSON & JOHNSON	<div><div></div>20.2 (1%)<div>-8%</div></div>		<div><div></div>-4</div>
7	FRAXIPARINE (1984)	Deep vein thromb., atrial fib., pulm. embolism	VIATRIS	<div><div></div>19.5 (1%)</div>	<div><div></div>31%</div>	<div><div></div>-2</div>
8	EYLEA (2011)	Diabetic Macular Edema, wet AMD, Retinal Vein Occlusion	BAYER	<div><div></div>19.2 (1%)</div>	<div><div></div>12%</div>	<div><div></div>-5</div>
9	ENTRESTO (2015)	Chronic heart failure	NOVARTIS	<div><div></div>17.1 (1%)</div>	<div><div></div>21%</div>	<div><div></div>-3</div>
10	STELARA (2009)	Psoriasis, CD1, UC2	JOHNSON & JOHNSON	<div><div></div>16.4 (1%)</div>	<div><div></div>7%</div>	<div><div></div>-6</div>
Top 10				223	25%	
Others				1,619	11%	
Total				1,842	13%	

Source: IQVIA Sell-in ex-MNF

The top 2 corporations maintained their 2023 ranking, with Novartis leading the way with 7% share

Top 10 ranking of corporations in Rx segment



#	Corporation	Top brands	Sales & market share [2024, EUR m]	Value growth / decline [2024 vs 2023]	Position change [2024 vs 2023; change in position]
1	NOVARTIS	Entresto, Jakavi, Kisqali	<div><div></div>133.9 (7%)</div>	<div><div></div>7%</div>	<div><div></div>0</div>
2	JOHNSON & JOHNSON	Darzalex, Erelada, Imbruvica	<div><div></div>114.0 (6%)</div>	<div><div></div>9%</div>	<div><div></div>0</div>
3	ROCHE	Phesgo, Ocrevus, Tecentriq	<div><div></div>73.6 (4%)</div>	<div><div></div>15%</div>	<div><div></div>+4</div>
4	ZENTIVA	Xanirva, Rilmex, Eleveon	<div><div></div>67.2 (4%)</div>	<div><div></div>6%</div>	<div><div></div>+1</div>
5	TAKEDA	Entyvio, Kiovig, Hyqvia	<div><div></div>66.8 (4%)</div>	<div><div></div>6%</div>	<div><div></div>+1</div>
6	PFIZER	Eliquis, Prevenar 13, Enbrel	<div><div></div>66.4 (4%)</div>	<div><div></div>1%</div>	<div><div></div>-2</div>
7	ABBVIE	Humira, Rinvoq, Skyrizi	<div><div></div>66.0 (4%)</div>	<div><div></div>11%</div>	<div><div></div>+2</div>
8	SANOFI	Clexane, Praluent, Dupixent	<div><div></div>64.8 (4%)</div>	<div><div></div>-1%</div>	<div><div></div>-5</div>
9	VIATRIS	Fraxiparine, Magnosolv, Thioctacid Meda	<div><div></div>61.4 (3%)</div>	<div><div></div>6%</div>	<div><div></div>-1</div>
10	NOVO NORDISK	Ozempic, Xultophy	<div><div></div>54.3 (3%)</div>	<div><div></div>12%</div>	<div><div></div>+2</div>
12	MSD	Keytruda, Gardasil	<div><div></div>51.6 (3%)</div>	<div><div></div>41%</div>	<div><div></div>+5</div>
Top 10			769	7%	
Others			1,074	5%	
Total			1,843	6%	

Source: IQVIA Sell-in ex-MNF

A large, dark blue rounded rectangle with a teal rounded rectangle on top and a teal rounded rectangle on the bottom left, all on the left side of the slide.

2 | Slovak Pharma Sector Overview


Consumer Health

The Consumer Health segment in SK grew faster in 2024 than Rx and has exceeded 1.0bn EUR for the first time

Total CH segment overview



CH segment components [EUR % and m, 2024]




2024 sales bn CZK	2024 vs 2023 YoY growth	
389	8.0%	OTC registered
330	8.8%	OTC non-registered
138	9.8%	Patient care
83	7.8%	Dermacosmetics
60	-1.7%	Nutritional supplements
14	-4.2%	Personal care

Price increase effect has had the most impact on overall growth; a significant number of new packs introduced

Industry elements of growth



SK CH segment value [m EUR, 2023 – 2024]



SK CH segment Elements of growth [m EUR, % of 2023, 2023 – 2024]



Note: 1) Mix effect Change in sales due to the change of consumer basket; shift towards higher volume of lower-priced products (smaller packs)

Source: IQVIA Pharmatrend data, Sell-out data, Retail Market

IQVIA | Výročná konferencia FARMAKON SR 2025 | CONFIDENTIAL – This document must not be shared with any 3rd party without previous IQVIA's written consent

On the left side of the slide, there are several overlapping rounded rectangular shapes in shades of blue and teal. A large dark blue shape is the most prominent, with a lighter blue shape above it and a teal shape below it. A thin blue line also curves around the bottom right of the dark blue shape.

2 | Slovak Pharma Sector Overview

Forecast


Slovak pharma segment expected to grow by 5.6%, with oncology products leading the expected growth in sales

Slovak pharma segment Forecast [Rx + regOTC]


Only Rx and registered OTC products are included in the forecast



SK sales value Retail/Hospital
[EUR bn, 2018-2028]



SK sales value by ATC classes
[% EUR, 2018-2028]



Note: 1) Forecast is only for Ox – Original Rx products protected by patent or with expired patent; Gx – Generic Rx products and registered CHC (OTC) products


Source: IQVIA Market Prognosis 2024-2028, February 2025

IQVIA | Výročná konferencia FARMAKON SR 2025 | CONFIDENTIAL – This document must not be shared with any 3rd party without previous IQVIA’s written consent



04

Q&A



Thank you for your attention.



Jozef Urbín

Healthcare Solutions Manager

Jozef.Urbín@iqvia.com

www.linkedin.com/in/jozef-urbín/